Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 25, 2025Journal of Materials Chemistry B

Nanotechnology-Based Strategies for Overcoming Clinical Limitations of PROTACs in Cancer Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

HCHanhee ChoJKJinseong KimHLHo-Yeon Lee

Discussion

Loading...

Member takes

Overview

Nanotechnology enhances degradation efficiency of PROTACs in cancer therapy, suggesting improved outcomes.

Key Points

  • Nanotechnology improves the efficacy of PROTACs, enhancing their potential in cancer therapy.
  • PROTACs can effectively degrade target proteins, differing from traditional therapies that only inhibit.
  • The study explores innovative strategies using nanotechnology to address adverse effects reported in clinical studies.
  • Advancements in nanotechnology may lead to safer and more effective cancer treatments while reducing side effects.

Cite This Study

Cho et al. (2025) studied this question.

synapsesocial.com/papers/68d5bd69dc445aa9033b03b0https://doi.org/10.1039/d5tb01162k
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities2025
  2. 2Recent Advances in Nanomedicine: Cutting-Edge Research on Nano-PROTAC Delivery Systems for Cancer Therapy2025
  3. 3Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions2025
  4. 4Evolution of proteolysis-targeting chimeras (PROTAC) technology to overcome challenges of antimicrobial resistance2025
  5. 5FDA-approved kinase inhibitors in PROTAC design, development and synthesis2025